A9Add image
AOD-9604
Weight LossSingleAlso known as: AOD9604, Anti-Obesity Drug 9604
A modified fragment of human growth hormone (the C-terminal 176–191 region) studied for fat metabolism without GH's other effects.
Half-life
0.5 h
Common dose
250 – 500 mcg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
AOD-9604 retains the lipolytic and fat-oxidation-stimulating portion of GH while losing the IGF-1 and growth-promoting effects. Mechanism may involve beta-3 adrenergic-receptor pathways.
Protocol notes
Typical research dosing is 250–500 mcg daily subcutaneously, often pre-fasted-state. Cycles of 8–12 weeks. Modest expected results compared with newer GLP-1 class peptides.
Reported side effects
Generally well-tolerated. Possible injection-site reactions, mild fatigue.